OTCMKTS:ADXS Ayala Pharmaceuticals (ADXS) Stock Forecast, Price & News $1.20 +0.20 (+20.00%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$1.10▼$1.2050-Day Range$0.65▼$1.2952-Week Range$0.65▼$7.20Volume16,264 shsAverage Volume7,660 shsMarket Capitalization$2.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort Interest About Ayala Pharmaceuticals (OTCMKTS:ADXS) StockAdvaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.Read More Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADXS Stock News HeadlinesMay 30, 2023 | americanbankingnews.comAyala Pharmaceuticals (OTCMKTS:ADXS) Upgraded to "Buy" by LADENBURG THALM/SH SHMay 28, 2023 | americanbankingnews.comShort Interest in Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS) Rises By 73.3%June 1, 2023 | Legacy Research (Affiliate) (Ad)“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.May 25, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate UpdateMay 23, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)May 22, 2023 | americanbankingnews.comAyala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.comMay 20, 2023 | health.usnews.comArmando AyalaJune 1, 2023 | Legacy Research (Affiliate) (Ad)“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.May 13, 2023 | americanbankingnews.comAyala Pharmaceuticals (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.comMay 12, 2023 | americanbankingnews.comAyala Pharmaceuticals, Inc. (OTCMKTS:ADXS) Sees Large Decrease in Short InterestMay 7, 2023 | americanbankingnews.comAyala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.comApril 28, 2023 | americanbankingnews.comAyala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.comApril 27, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingApril 21, 2023 | americanbankingnews.comAyala Pharmaceuticals (OTCMKTS:ADXS) Coverage Initiated at StockNews.comApril 20, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)April 13, 2023 | uk.finance.yahoo.comAyala Pharmaceuticals, Inc. (ADXS)April 12, 2023 | americanbankingnews.comAyala Pharmaceuticals (OTCMKTS:ADXS) Receives New Coverage from Analysts at StockNews.comApril 12, 2023 | forbes.comHubei Biocause PharmaceuticalApril 12, 2023 | americanbankingnews.comAyala Pharmaceuticals (OTCMKTS:ADXS) Now Covered by StockNews.comApril 10, 2023 | americanbankingnews.comAyala Pharmaceuticals (OTCMKTS:ADXS) Now Covered by Analysts at StockNews.comApril 7, 2023 | americanbankingnews.comAyala Pharmaceuticals (OTCMKTS:ADXS) Earns Sell Rating from Analysts at StockNews.comApril 6, 2023 | americanbankingnews.comAyala Pharmaceuticals (OTCMKTS:ADXS) Coverage Initiated by Analysts at StockNews.comApril 5, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Ayala Pharmaceuticals (OTCMKTS:ADXS)April 4, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Ayala Pharmaceuticals (OTCMKTS:ADXS)March 30, 2023 | americanbankingnews.comAyala Pharmaceuticals (OTCMKTS:ADXS) Research Coverage Started at StockNews.comMarch 3, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring CommitteeSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADXS Company Calendar Last Earnings9/09/2021Today6/01/2023Next Earnings (Estimated)6/06/2023Fiscal Year End10/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ADXS CUSIPN/A CIK1100397 Webwww.advaxis.com Phone(609) 452-9813Fax609-452-9818Employees14Year Founded2002Profitability EPS (Most Recent Fiscal Year)($8.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,360,000.00 Net MarginsN/A Pretax Margin-5,723.60% Return on Equity-57.87% Return on Assets-51.87% Debt Debt-to-Equity RatioN/A Current Ratio11.19 Quick Ratio11.18 Sales & Book Value Annual Sales$3.24 million Price / Sales0.67 Cash FlowN/A Price / Cash FlowN/A Book Value$13.01 per share Price / Book0.09Miscellaneous Outstanding Shares1,816,000Free Float1,810,000Market Cap$2.18 million OptionableOptionable Beta2.44 Social Links Key ExecutivesKen BerlinPresident, Chief Executive Officer & DirectorIgor GitelmanVP-Finance, Chief Financial & Accounting OfficerAndres A. GutiérrezChief Medical Officer & Executive Vice PresidentMichael GraceVice President-Technical OperationsKey CompetitorsNovaBay PharmaceuticalsNYSE:NBYAngioSomaOTCMKTS:SOANQ BioMedOTCMKTS:QBIOAthenexNASDAQ:ATNXSciSparcNASDAQ:SPRCView All Competitors ADXS Stock - Frequently Asked Questions Should I buy or sell Ayala Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADXS shares. View ADXS analyst ratings or view top-rated stocks. How have ADXS shares performed in 2023? Ayala Pharmaceuticals' stock was trading at $1.20 on January 1st, 2023. Since then, ADXS shares have increased by 0.0% and is now trading at $1.20. View the best growth stocks for 2023 here. Are investors shorting Ayala Pharmaceuticals? Ayala Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 5,200 shares, an increase of 73.3% from the April 30th total of 3,000 shares. Based on an average daily trading volume, of 12,900 shares, the days-to-cover ratio is presently 0.4 days. View Ayala Pharmaceuticals' Short Interest. When is Ayala Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 6th 2023. View our ADXS earnings forecast. How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS) issued its quarterly earnings results on Thursday, September, 9th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The biotechnology company had revenue of $0.25 million for the quarter. What is Ayala Pharmaceuticals' stock symbol? Ayala Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ADXS." How do I buy shares of Ayala Pharmaceuticals? Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ayala Pharmaceuticals' stock price today? One share of ADXS stock can currently be purchased for approximately $1.20. How much money does Ayala Pharmaceuticals make? Ayala Pharmaceuticals (OTCMKTS:ADXS) has a market capitalization of $2.18 million and generates $3.24 million in revenue each year. The biotechnology company earns $-14,360,000.00 in net income (profit) each year or ($8.93) on an earnings per share basis. How can I contact Ayala Pharmaceuticals? Ayala Pharmaceuticals' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The official website for the company is www.advaxis.com. The biotechnology company can be reached via phone at (609) 452-9813, via email at ir@advaxis.com, or via fax at 609-452-9818. This page (OTCMKTS:ADXS) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.